History of Medicine
Aug 2019
Gail B. Karet, PhD
Since the 1960s, drug names have been products of complex, multiparty negotiations in which interests of patients, pharmaceutical firms, clinicians, and US and international regulators must be balanced.
AMA J Ethics. 2019; 21(8):E686-696. doi:
10.1001/amajethics.2019.686.